INTRODUCTION

Worldwide, more than 700,000 cases of head and neck cancer (including cancers of the oral cavity, pharynx, and larynx) are diagnosed each year. Tobacco smoking and alcohol drinking are the major risk factors for these cancers, their joint effect being at least multiplicative. Human papillomavirus (HPV) is also a recognized cause of a subset of head and neck...
squamous cell carcinomas (HNSCC). While the causal role of HPV16 in oropharyngeal cancer is well established, the role of other HPV genotypes or the association between HPV and other subsites of HNSCC is still debated. The manner in which tobacco, alcohol, and HPV interact on HNSCC risk remains unclear, with conflicting results. Some studies demonstrated a lack of association with tobacco and alcohol in HPV16-positive HNSCC. Other more recent studies have shown that tobacco smoking and alcohol drinking have rather an independent role in the etiology of HPV16-positive oropharyngeal cancer.

Guadeloupe and Martinique are two French overseas territories in the French West Indies (FWI). The population is predominantly Afro-Caribbean. Their incidence rates of head and neck cancer, especially in men, are among the highest in Latin America and the Caribbean, despite a relatively low prevalence of tobacco smoking and alcohol drinking. The prevalence of HPV in HNSCC and the distribution of HPV genotypes may vary substantially according to geographical regions and ethnicity. Racial/ethnic differences in the effects of tobacco and alcohol on HNSCC have also been suggested.

In order to elucidate the etiology of HNSCC in the FWI, we conducted a population-based case-control study. It was previously shown that oral infection with high-risk HPV was associated with an increase in risk of HNSCC. Although oral infection with HPV16 was associated with oropharyngeal cancer, HPV16 was not the predominant genotype and there was a higher prevalence of other high-risk HPV genotypes in cases than in controls.

In this study, we aimed to investigate the role of tobacco and alcohol consumption on the occurrence of HNSCC, and the joint effects of these factors with oral HPV infection. To our knowledge, this is the first study on this topic in an Afro-Caribbean population.

2 | METHODS

2.1 | Study population, data, and specimen collection

We extended a large population-based case-control study previously conducted in mainland France to the overseas French departments Guadeloupe and Martinique. The details of this study, the ICARE study, have been described elsewhere. A similar protocol and questionnaire were used for the study in the FWI, with some adaptations to the French West Indian context. Briefly, cases were identified in collaboration with the cancer registries. These registries have been in place since 1983 for Martinique and 2008 for Guadeloupe, and use standardized procedures for the recording of all cancer cases in each of these regions. Eligible cases were patients residing in the FWI, aged between 18-75 years old, newly diagnosed with a primary, malignant, and histologically confirmed tumor of the oral cavity, pharynx, sinonasal cavities, and larynx between 1 April 2013 and 30 June 2016. Random digit dialing was used to select controls from the general population, using incidence density sampling. Controls were frequency matched to the cases by sex, age and region of residence (Guadeloupe and Martinique). Further stratification was applied to make the distribution by socioeconomic status of the control group similar to that of the general population.

Face-to-face interviews were conducted with cases and controls using a standardized questionnaire to ascertain sociodemographic characteristics and risk factors, in particular lifetime tobacco and alcohol consumption. During these interviews, Oragene® OG-500 kits (DNA Genotek) were used to collect a saliva sample from participants who gave their consent.

We initially identified 257 cases as potentially eligible, and 192 (74.7%) gave their consent to participate and were interviewed. After further review of clinical and pathological reports, 22 did not satisfy the inclusion criteria and were excluded from the study. Among the remaining 170 cases, 114 (72.3%) agreed to provide a saliva sample. Among the 497 eligible controls, 405 (81.5%) responded to the questionnaire and among them, 311 (76.2%) provided a saliva sample.

2.2 | HPV detection and genotyping

Human papillomavirus-integrated DNA from saliva samples was detected with the INNO-LiPA® kit, according to the manufacturer’s instructions (INNO-LiPA HPV Genotyping Extra; Innogenetics). The INNO-LiPA HPV genotyping assay allows the detection of 32 HPV genotypes, which were classified as high-risk HPV types (HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, HPV68), probable high-risk (HPV26, HPV53, HPV66, HPV70, HPV73, HPV82), low-risk (HPV06, HPV11, HPV40, HPV42, HPV43, HPV44, HPV54, HPV61, HPV81), and other (HPV62, HPV67, HPV83, HPV89). The method for HPV detection has been described in detail elsewhere.

2.3 | Exposure variables

Detailed information on lifetime cigarette smoking history was recorded, for each period of identical smoking habits. The questionnaire included information on age at start and end of the period, number of cigarettes per day or per week, type of tobacco (blond vs black), filtered or not, inhalation pattern, and whether or not the product was manufactured or hand-rolled. Ever cigarette smokers were defined as persons who smoked at least 100
cigarettes in their lifetime. Ex-smokers were defined as persons who stopped smoking for at least 2 years. Smoking quantity was defined as the average number of cigarettes per day over the lifetime, and categorized into three groups (1-10, 11-20 and >20 cigarettes per day). Smoking duration was expressed in years and was divided into 4 categories (1-20, 21-30, 31-40, >40 years). Never smoker was the reference category used for all smoking-related variables in our analyses. Dichotomous variables (ever/never) were created for smoking pipes, cigars, chewing, and snuffing tobacco.

Lifetime alcohol drinking information was recorded as well, with for each period of regular consumption, the age at beginning and end, and the number of standard glasses per day, week or month for each type of alcoholic beverage (wine, beer, rum, and other strong spirits). For each type of beverage, ever daily alcohol drinking was defined as at least one glass per day during at least 1 year. The average number of glasses per day was calculated over the lifetime, regardless of the type of beverage, and categorized into three groups (<1, 1-5, and >5 glasses per day). The reference category comprised subjects who never drank alcohol or who had drunk less than one glass per week. Alcohol duration was expressed in years and was divided into three categories (≤30, 31-45, >45 years). Exposure to HPV was assessed in several manners. Subjects with at least one HPV infection of any type were classified as HPV-positive, others were referred as HPV-negative. The group of HPV-positive was further divided into two categories: high-risk-HPV-positive (at least one HPV type were classified as HPV-positive, others were referred as HPV-negative. A final binary variable was used for the exposure high-risk group) and non-high-risk-HPV-positive. A final binary variable was used for the exposure high-risk-HPV: high-risk-HPV-positive vs high-risk-HPV-negative, the latter category grouping HPV-negative and non-high-risk-HPV-positive.

2.4  Statistical analysis

The current analysis was restricted to squamous cell carcinomas of the oral cavity (International Classification of Diseases 10th revision codes C00.3-C00.9, C02.0-C02.3, C03.0, C03.1, C03.9, C04.1, C04.8, C04.9, C05.0, C06.0-C06.2, C06.8, and C06.9, n = 35), the oropharynx (ICD-10 codes C01.9, C02.4, C05.1, C05.2, C09, C10, C14.2, n = 58), the hypopharynx (ICD-10 codes C12-C13, n = 19) and the larynx (ICD-10 codes C32, n = 32). Our analysis included 145 cases and 405 controls. The association between smoking, alcohol and oral HPV infection and the occurrence of HNSCC was assessed by estimating odds ratios (ORs) adjusted for age, sex and recruitment site, and their 95% confidence intervals (CIs), using logistic regression models. The models for tobacco smoking were further adjusted for alcohol consumption. Models estimating the effect of alcohol were adjusted for smoking quantity and duration. Odds ratios associated with oral HPV were adjusted for smoking quantity, duration, and alcohol consumption. Two-way interaction on a multiplicative scale was assessed by estimating Ψ, the multiplicative interaction parameter as follows, Ψ = OR11/(OR01*OR10). The 95% CI for Ψ was determined using the CI for the interaction term in the multivariate model. Two-way interaction on an additive scale was assessed using the relative excess risk due to interaction (RERI), RERI = OR11 − OR10 − OR01 + 1. Asymptotic 95% CI were calculated for the RERI as described elsewhere. We also conducted analyses by cancer site (oropharynx/ non oropharynx). We grouped oral cavity, hypopharynx, and larynx because of sample size constraints.

Human papillomavirus status was missing for 147 (27%) subjects (53 cases and 94 controls) who refused to provide a saliva sample, and for three controls for whom the quality of the specimen was considered inadequate for HPV detection. In addition, missing data were observed for smoking status (one case) smoking quantity (19 cases, 3 controls), smoking duration (6 cases, 1 control), alcohol quantity (4 controls), and alcohol duration (27 cases 56 controls). We used multiple imputations by chained equations to deal with missing data. The imputation model contained all the basic characteristics of the study subjects (age, sex, recruitment site and education level), variables related to alcohol and smoking (ever daily alcohol drinking, quantity of alcohol, smoking status, smoking duration, and smoking quantity), HPV status (low-risk, probable high-risk, high-risk, and other HPV types) and the case-control status. All variables in the imputation model which had missing values were imputed for our analyses. We generated 20 datasets. We also performed a complete case analysis, on a dataset containing only observed data. Results were similar to those from the imputed datasets, despite wider confidence intervals (see Supporting Information). Statistical analysis was performed using SAS 9.4 software (SAS Institute).

3  RESULTS

3.1  Characteristics of study population

Table 1 shows socio-demographic characteristics of HNSCC cases and controls. The majority of subjects in our study were between 55 and 64 years old and were men. A little under half of the cases had only primary school education (42.8%) compared to 23.2% of the controls.

3.2  Tobacco, alcohol, oral HPV, and HNSCC risk

Table 2 shows multivariate ORs of HNSCC and 95% CI associated with tobacco smoking, alcohol drinking and oral HPV.
Current smokers were significantly 11 times more likely to develop HNSCC compared to never smokers. Ex-smokers were only twice as likely to develop a HNSCC compared to never smokers. The risk increased with the quantity and duration of tobacco smoking. Significant increases in risk by more than 10-fold were observed for more than 20 cigarettes per day, and for more than 30 years. We studied as well the combination between smoking quantity and duration. We observed that duration had a greater role in HNSCC etiology than the quantity. Persons who smoked for shorter periods of time (less than 30 years) had a lower risk for developing HNSCC regardless of the quantity of cigarettes smoked per day.

Compared to never smokers, the risk of HNSCC was slightly greater for the persons who smoked only black tobacco than blond tobacco alone (OR = 5.97, 95% CI = 2.80-12.73; OR = 4.67, 95% CI = 2.55-8.54, respectively) (data not shown). The ORs were higher for those who inhaled deeply cigarette fumes (OR = 5.20, 95% CI = 2.94-9.18) than for those who never inhaled (OR = 3.76, 95% CI = 1.57-8.96) or inhaled a little (OR = 3.53, 95% CI = 1.85-6.75) (data not shown). Cigarettes without filters (2.5%), hand-rolled cigarettes (2.8%), pipe (5.0%), and cigars (3.6%) were uncommon in our study population and were not associated with the risk of HNSCC (data not shown). It should be noted that all cigar smokers and all pipe smokers but one case had also smoked cigarettes. No subject had chewed tobacco and only one case had snuffed.

We observed a significant inverse association for those who drank less than one glass per day in relation to HNSCC, when compared to nondrinkers. The daily consumption of rum and beer increased the risk significantly by two fold compared to the persons who never drank rum or beer daily. In contrast, daily consumption of wine and other strong spirits did not increase the risk significantly compared to nondaily drinkers.

Rum was the most frequently consumed alcoholic beverage in our study population regardless of case-control status. The daily consumption of rum and beer increased the risk significantly by two fold compared to the persons who never drank rum or beer daily. In contrast, daily consumption of wine and other strong spirits did not increase the risk significantly compared to nondaily drinkers.

In terms of oral HPV infections, no significant association with HNSCC was found for persons tested positive for HPV when compared to HPV-negative subjects. Non-high-risk HPV types as well did not show any significant difference in risk to HPV-negative subjects. On the other hand, subjects positive for Hr-HPV types were twice as likely to develop HNSCC compared to Hr-HPV-negative subjects. Among Hr-HPV types, we detected HPV16 in 4 cases and 2 controls. HPV18 was found only in 2 cases and 1 control. The other Hr-HPV types which were detected in greater proportion among cases than controls were HPV33 (3 cases 1 control), HPV51 (3 cases 0 controls), HPV52 (8 cases 12 controls), and HPV56 (5 cases 6 controls).

We analyzed tobacco, alcohol, and oral HPV risk among oropharyngeal and non-oropharyngeal subsites separately; these results did not change in terms of direction of the association observed in the analyses with all HNSCC cases (data not shown).

### 3.3 Joint effect of risk factors and HNSCC risk

Table 3 shows the multivariate ORs, their 95% CIs, and measures of two-way interaction for combined exposures to risk factors, for HNSCC and by subsite. Compared to never smokers and nondrinkers, never smokers who drank alcohol daily had a nonsignificant increase in HNSCC risk (OR = 2.01, 95% CI = 0.87-4.61) whereas smokers who did not drink alcohol were 3 times more likely to have HNSCC (OR = 3.57, 95% CI = 1.85-6.75) (data not shown). The joint effect of tobacco and alcohol was more than multiplicative but not significant for HNSCC (Ψ = 2.01, 95% CI = 0.75-5.37). However, a significant interaction was observed on the

| Characteristics | Cases n = 145 col% | Controls n = 405 col% |
|-----------------|--------------------|-----------------------|
| Age (y)         |                    |                       |
| <45             | 3 2.1              | 62 15.3               |
| 45-54           | 40 27.6            | 107 26.4              |
| 55-64           | 61 42.1            | 129 31.9              |
| >65             | 41 28.3            | 107 26.4              |
| Sex             |                    |                       |
| Women           | 18 12.4            | 99 24.4               |
| Men             | 127 87.6           | 306 75.6              |
| Recruitment site|                    |                       |
| Guadeloupe      | 95 65.5            | 245 60.5              |
| Martinique      | 50 34.5            | 160 39.5              |
| Education level |                    |                       |
| Primary school  | 62 42.8            | 94 23.2               |
| Secondary school| 51 35.2            | 161 39.8              |
| High school diploma | 17 11.7 | 53 13.1               |
| Tertiary education | 15 10.3          | 97 24.0               |

Note: French West Indies, 2013-2016.
Abbreviation: HNSCC, head and neck squamous cell carcinomas.
# Table 2: Multivariate OR of HNSCC and 95% CI associated with tobacco smoking, alcohol drinking, and oral HPV infection

| Risk factor                        | Cases | Controls | OR    | 95% CI  |
|------------------------------------|-------|----------|-------|---------|
|                                    | n = 145 | col% | n = 405 | col% |                   |
| **Tobacco smoking**                |       |        |       |         |
| Never smoker                       | 30    | 21.8   | 263   | 64.9   | 1                   |
| Smoking status                     |       |        |       |         |
| Current smoker                     | 88    | 61.1   | 52    | 12.8   | 11.59               | 6.69-20.08 |
| Former smoker                      | 26    | 18.1   | 90    | 22.2   | 2.28                | 1.24-4.17  |
| Missing                            | 1     | 0      |       |        |                     |
| **Quantity (cigarette per day)**   |       |        |       |         |
| 1-10                               | 35    | 27.8   | 71    | 17.7   | 4.17                | 2.33-7.46  |
| 11-20                              | 35    | 27.8   | 51    | 12.7   | 6.11                | 3.39-11.04 |
| >20                                | 26    | 20.6   | 17    | 4.2    | 10.69               | 4.89-23.41 |
| Missing                            | 19    | 3      |       |        |                     |
| **Duration (y)**                   |       |        |       |         |
| 1-20                               | 9     | 6.5    | 57    | 14.1   | 1.43                | 0.64-3.23  |
| 21-30                              | 17    | 12.2   | 37    | 9.2    | 3.94                | 1.92-8.07  |
| 31-40                              | 42    | 30.2   | 23    | 5.7    | 12.25               | 6.16-24.37 |
| >40                                | 41    | 29.5   | 24    | 5.9    | 13.28               | 6.61-26.68 |
| Missing                            | 19    | 3      |       |        |                     |
| ≤20 cigarettes per day             |       |        |       |         |
| During ≤ 30 y                      | 16    | 12.8   | 84    | 21.0   | 2.00                | 1.05-3.81  |
| During > 30 y                      | 53    | 42.4   | 37    | 9.2    | 12.19               | 6.68-22.24 |
| >20 cigarettes per day             |       |        |       |         |
| During ≤ 30 y                      | 6     | 4.8    | 7     | 1.8    | 7.10                | 2.13-23.70 |
| During > 30 y                      | 20    | 16.0   | 10    | 2.5    | 15.38               | 6.03-39.19 |
| Missing                            | 20    | 4      |       |        |                     |
| **Alcohol quantity**               |       |        |       |         |
| Never or occasionally              | 51    | 35.2   | 216   | 53.9   | 1                   | ref            |
| <1                                 | 8     | 5.5    | 73    | 18.2   | 0.40                | 0.17-0.93     |
| 1-5                                | 45    | 31.0   | 84    | 21.0   | 1.24                | 0.70-2.20     |
| >5                                 | 41    | 28.3   | 28    | 7.0    | 2.36                | 1.18-4.73     |
| Missing                            | 0     | 4      |       |        |                     |
| **Alcohol duration**               |       |        |       |         |
| ≤30                                | 25    | 17.2   | 129   | 31.9   | 1                   | ref            |
| 31-45                              | 67    | 46.2   | 161   | 39.8   | 1.69                | 0.88-3.23     |
| >45                                | 26    | 17.9   | 59    | 14.8   | 3.56                | 1.45-8.74     |
| Missing                            | 27    | 56     |       |        |                     |
| **Type of beverage**               |       |        |       |         |
| Wine                               | 38    | 26.2   | 54    | 13.3   | 1.35                | 0.76-2.39     |
| Beer                               | 34    | 23.5   | 35    | 8.6    | 1.83                | 0.98-3.42     |
| Rum                                | 75    | 51.7   | 61    | 15.1   | 2.90                | 1.74-4.84     |
| Other strong spirits               | 13    | 9.0    | 12    | 3.0    | 1.82                | 0.68-4.89     |

(Continues)
TABLE 2  (Continued)

| Risk factor       | Cases | Controls |
|-------------------|-------|----------|
|                   | n = 145 | col% | n = 405 | col% | OR | 95% CI |
| Oral HPV status\(^c\) |       |       |        |       |    |       |
| HPV-negative      | 60    | 65.2  | 228    | 73.9 | ref |        |
| Any HPV           | 32    | 34.8  | 80     | 26.1 | 1.44| 0.82-2.53 |
| HPV-Non-high risk | 13    | 14.1  | 50     | 16.3 | 0.80| 0.35-1.83 |
| HPV-High risk     | 19    | 20.7  | 30     | 9.8  | 2.37| 1.13-4.97 |
| Missing           | 53    | 97    |        |       |    |        |

Note: French West Indies, 2013-2016.

Abbreviations: CI, confidence interval; HNSCC, head and neck squamous cell carcinomas; HPV, human papillomavirus; OR, odds ratio.

\(^a\)Model adjusted for age, sex, recruitment site, alcohol consumption (glasses per day).

\(^b\)Model adjusted for age, sex, recruitment site, tobacco smoking as the combination of quantity (cigarettes per day) and duration (y).

\(^c\)Model adjusted for age, sex, recruitment site, tobacco smoking status, alcohol consumption (glasses per day).

TABLE 3  Multivariate OR, their 95% CI, and measures of two-way interactions of combined exposures between risk factors for HNSCC and by subsite

| Risk factor combinations | All cases | Oropharynx | Non-Oropharynx |
|--------------------------|-----------|------------|----------------|
|                          | OR (95% CI) | OR (95% CI) | OR (95% CI)    |
| Smoking and alcohol\(^a\) |           |            |                |
| Never smoker-non drinker | 1 (ref)    | 1 (ref)    | 1 (ref)        |
| Never smoker-drinker     | 2.01 (0.87-4.61) | 2.81 (0.75-10.48) | 1.79 (0.64-5.01) |
| Ever smoker-non drinker  | 3.57 (1.89-6.74) | 5.59 (2.06-15.20) | 2.75 (1.24-6.11) |
| Ever smoker-drinker      | 14.39 (8.02-25.82) | 19.37 (7.56-49.61) | 13.23 (6.62-26.45) |
| \(\Psi\) (95% CI)        | 2.01 (0.75-5.37) | 1.23 (0.28-5.67) | 2.69 (0.80-9.11) |
| RERI (95% CI)            | 9.82 (3.06-16.57) | 11.96 (−1.32 to 25.24) | 9.69 (2.25-17.13) |

Smoking and Hr-HPV\(^b\)

| Never smoker-Hr-HPV− | 1 (ref) | 1 (ref) | 1 (ref) |
| Never smoker-Hr-HPV+ | 4.74 (1.45-15.50) | 5.23 (1.10-24.86) | 3.26 (0.64-16.60) |
| Ever smoker-Hr-HPV− | 6.30 (3.44-11.52) | 8.82 (3.47-22.38) | 5.11 (2.46-10.61) |
| Ever smoker-Hr-HPV+ | 8.98 (3.85-20.94) | 10.09 (2.94-34.56) | 7.53 (2.77-20.43) |
| \(\Psi\) (95% CI) | 0.30 (0.07-1.24) | 0.22 (0.03-1.38) | 0.45 (0.07-2.94) |
| RERI (95% CI) | −1.07 (−8.28 to 6.15) | −2.97 (−14.35 to 8.42) | 0.16 (−6.67 to 6.99) |

Alcohol and Hr-HPV\(^c\)

| Non drinker-Hr-HPV− | 1 (ref) | 1 (ref) | 1 (ref) |
| Non drinker-Hr-HPV+ | 4.43 (1.50-13.11) | 4.76 (1.31-17.32) | 3.39 (0.69-16.78) |
| Drinker-Hr-HPV− | 3.20 (1.76-5.82) | 3.85 (1.65-8.97) | 3.06 (1.47-6.39) |
| Drinker-Hr-HPV+ | 3.33 (1.27-8.73) | 2.40 (0.62-9.30) | 3.70 (1.24-11.09) |
| \(\Psi\) (95% CI) | 0.24 (0.06-0.99) | 0.13 (0.02-0.80) | 0.36 (0.05-2.40) |
| RERI (95% CI) | −3.30 (−8.01 to 1.42) | −5.21 (−11.93 to 1.52) | −1.75 (−6.93 to 3.43) |

Note: French West Indies, 2013-2016.

Abbreviations: CI, confidence interval; HNSCC, head and neck squamous cell carcinomas; HPV, human papillomavirus; OR, odds ratio; Phi (\(\Psi\)), measure of interaction on a multiplicative scale (interaction term); RERI, relative excess risk due to interaction.

\(^a\)Model adjusted for age, sex, recruitment site.

\(^b\)Model adjusted for age, sex, recruitment site and ever daily alcohol consumption.

\(^c\)Model adjusted for age, sex, recruitment site, tobacco smoking as the combination of quantity (cigarettes per day) and duration (y).
additive scale for tobacco and alcohol (RERI = 9.82, 95% CI = 3.06 to 16.57). Never smokers positive for Hr-HPV were significantly more likely to have HNSCC when compared with Hr-HPV-negative never smokers (OR = 4.74, 95% CI = 1.45-15.50). Moreover, Hr-HPV-negative ever smokers had an even greater risk of HNSCC (OR = 6.30, 95% CI = 3.44-11.52). Negative interactions, although not significant, between Hr-HPV and smoking were observed on both the multiplicative (Ψ = 0.30, 95% CI = 0.07-1.24) and the additive scale (RERI = −1.07, 95% CI = −8.28 to 6.15). Hr-HPV-positive nondrinkers and Hr-HPV-negative drinkers were both significantly more likely to have HNSCC than Hr-HPV-negative nondrinkers. The joint effect of alcohol and Hr-HPV on HNSCC risk was less than additive (RERI = −3.30, 95% CI = −8.01 to 1.42) and significantly less than multiplicative (Ψ = 0.24, 95% CI = 0.06-0.99). Negative interactions involving oral Hr-HPV were consistently more marked for alcohol than tobacco. We also performed the above interaction analyses on oropharyngeal and non-oropharyngeal squamous cell carcinomas separately. Although the difference in effect size and trends did not differ significantly between subsites, the effect of all the studied risk factors appeared to be of greater magnitude for the oropharynx than the non-oropharynx cases. In particular, oral Hr-HPV in never smokers and in nondrinkers was found to be significant for only oropharyngeal cancer.

Table 4 shows the associations for combined exposures to tobacco smoking and alcohol drinking, stratified by Hr-HPV status. In the Hr-HPV-negative subgroup, the trend was similar to the effect sizes and the measures of interaction for all study participants together. The Hr-HPV-positive subgroup on the other hand had overall lower effect sizes for the tobacco-alcohol profiles compared to their Hr-HPV-negative counterparts.

### TABLE 4

| Risk factor combinations | HPV-Hr-negative | HPV-Hr-positive |
|--------------------------|-----------------|-----------------|
|                          | OR   | 95% CI | OR   | 95% CI |
| Smoking and alcohola     |      |        |      |        |
| Never smoker-non drinker | 1    | Ref    | 1    | Ref    |
| Never smoker drinker     | 3.09 | 1.03-9.22 | 0.56 | 0.05-6.72 |
| Ever smoker-non drinker  | 4.89 | 1.99-12.03 | 1.41 | 0.27-7.32 |
| Ever smoker-drinker      | 23.43 | 10.11-54.30 | 3.57 | 0.88-14.48 |
| Ψ (95% CI)               | 1.55 | 0.43-5.58 | 4.52 | 0.21-97.84 |
| RERI (95% CI)            | 16.45 | 1.76-31.16 | 2.59 | −1.65 to 6.84 |

Note: French West Indies, 2013-2016.

Abbreviations: CI, confidence interval; HNSCC, head and neck squamous cell carcinomas; HPV, human papillomavirus; OR, odds ratio; RERI, relative excess risk due to interaction; Ψ, multiplicative interaction parameter.

aModel adjusted for age, sex, recruitment site.

### DISCUSSION

Our findings provide new insight into the role of tobacco, alcohol, and oral HPV infection and their combined effects on the occurrence of HNSCC in the FWI.

Similarly to other studies, we found that the risk of HNSCC increased with the duration and intensity of smoking, and the duration had a greater effect than the average number of cigarettes per day. Due to its high alcohol content, rum was found to be the beverage which conferred the greatest risk of HNSCC compared to other alcoholic beverages. This observed association for rum is likely to result from it being the most frequently consumed alcoholic beverage in the FWI rather than an independent effect of the alcohol concentration. The inverse association we found for light alcohol drinking (<1 glass per day) was consistent with a French study; however, a recent meta-analysis reported pooled estimates that suggested rather a nonsignificant positive association between light alcohol drinking and head and neck cancer. The increased risk we observed for the long period of alcohol consumption was also supported by a study from the INHANCE consortium. Although not significant we observed a more than multiplicative effect of the combined of exposure to tobacco and alcohol on HNSCC risk which was of similar magnitude to a study conducted within the INHANCE Consortium. The few studies assessing the additive interaction for tobacco and alcohol conducted their analysis in individual HNSCC subsites and reported super-additive interactions of varying degrees. Oral Hr-HPV infections were significantly associated with HNSCC, regardless of Hr-HPV genotype. A study conducted in Canada did not find any significant association with HNSCC and Hr-HPV types excluding HPV16. In our study, only four cases and two controls were positive for HPV16, and the effect of Hr-HPV on HNSCC was maintained after removing HPV16-positive subjects. These results could be
suggestive of a greater role of non-HPV 16 high risk types in HNSCC carcinogenesis in the FWI compared to other populations, as also suggested for cervical infections.30

Concerning the joint effect of tobacco and HPV, and alcohol and HPV, we found some evidence of a negative interaction on both the additive and multiplicative scale. In particular, the combined effect of alcohol and HPV was significantly less than multiplicative contrary to previous studies which revealed more synergistic relationships.11,31,32 Despite the negative interactions that we found, tobacco and alcohol still increased the risk of HNSCC regardless of HPV status. The effect of tobacco, alcohol and of the combined exposure to tobacco and alcohol were however substantially lower in HPV-positive than in HPV-negative HNSCC, which is indicative of a more pre-dominant role of tobacco and alcohol in HPV-negative HNSCC as described in previous studies which investigated HPV 16 specifically.5,7,8

We studied the prevalence of oral HPV infection and we are not able to distinguish between recent and long-term infections, which complicates the interpretation of the results on the interactions. Smoking has been shown to increase the likelihood of acquisition33 and persistence34–36 of oral HPV infection in some studies, whereas other studies found no association between smoking and oral HPV incidence34–37 or persistence of oral HPV infection.40,41 It has been suggested that smoking-induced secretory leukocyte protease inhibitor expression may prevent HPV infections.42,43 Additional studies are needed to fully elucidate the complex role of smoking in oral HPV natural history. Alcohol intake was not found to be associated with incidence33,34,37,38 or persistence.44 It has been suggested that expression may prevent HPV infections.42,43

Analyses by subsite did not reveal important differences with regards to the effects of tobacco and alcohol; although point estimates were higher in oropharyngeal cancer than in non-oropharyngeal cancer, the confidence intervals were wide and the effect of traditional risk factors was similar in both subsites, as previously shown.9

Our data on the joint effect of tobacco, alcohol and Hr-HPV on the occurrence of oropharyngeal cancer were supported by previous reports.9,10 We found that Hr-HPV was associated with a significant increase in risk of oropharyngeal cancer in never smokers and in nondrinkers. These significant associations were not present in the non-oropharyngeal cases. In addition, the measures of interaction for the joint exposure with each of the risk factors and oral Hr-HPV-positive infections were more marked in the oropharyngeal cases than the non-oropharyngeal cases. Furthermore, the significant sub-multiplicative interaction between alcohol and Hr-HPV was observed exclusively in the oropharynx. These observations support an etiological role of oral Hr-HPV specific to oropharyngeal cancer, as in previous studies.7,8,31,32 We demonstrated that alcohol alone did not play a role in Hr-HPV-positive oropharyngeal cancer as described previously.9,10 Our results did not provide strong evidence for a role of tobacco in oropharyngeal carcinogenesis regardless of HPV status, contrarily to a recent study which emphasized the existence of a positive association in HPV 16-related oropharyngeal cancer.9

Our study presents some limitations. The statistical power was low to detect interactions. In addition, the small sample size limited the detail in our analyses. In particular, we were not able to assess three-way interactions by subsite as we would have liked with tobacco, alcohol and Hr-HPV. We had 27% missing data for HPV in our sample. To handle missing data, we used a multiple imputation procedure that has been shown to result in less biased and more precise estimates than the exclusion of individuals with missing data.22 The case-control design coupled with the lack of temporal sequence in HPV data made it difficult to put forward a more precise mechanism between the risk factors and HPV in HNSCC risk. We had very few subjects infected with HPV 16, which made comparisons with other studies difficult.7–10 Furthermore, the use of oral HPV detection to assess the HPV status may have resulted in misclassification, which is however likely to be nondifferential. Oral HPV detection has been shown to have good specificity but moderate sensitivity for HPV-positive HNSCC tumors.44 Despite the limitations imposed by oral HPV detection, this method is indicative of the site of infections compared to HPV serology which is not site-specific.

Considering the participation of the local cancer registries in the selection of cases and the methods employed to select the controls, we believe that no major selection bias has occurred in this study. Cases included in our study had a distribution by age, sex and cancer site similar to that of the cases recorded in the cancer registries; therefore, our sample can be considered representative of the HNSCC cases. The selection method for the controls was previously shown to produce unbiased samples, thus our controls could be regarded as being representative of persons of similar age and sex from the general population.20 We confirmed the representativeness of the tobacco and alcohol distribution in our control group to FWI population after comparison with the data from a national health survey.12

5 CONCLUSION

This is the first case-control study to investigate the role of tobacco smoking, alcohol drinking and oral HPV infection in an Afro-Caribbean population. We showed that these risk factors have significant independent effects on the occurrence of HNSCC. Overall, our findings suggest a less important role of tobacco and alcohol in Hr-HPV-positive HNSCC. The precise mechanisms driving these interactions on HNSCC risk are yet to be elucidated and further investigations are warranted notably on the interaction of these three risk factors simultaneously.
ACKNOWLEDGMENTS
The authors thank our clinical research associates Lucina Lipau and Audrey Pomier for their help in data collection. Aviane Auguste was supported by a grant from the "Ligue contre le Cancer, comité d’Ille-et-Vilaine" for this work. This study was funded by the French National Cancer Institute (Institut National du Cancer) and the Cancéropôle Ile-de-France.

CONFLICT OF INTEREST
The authors have no conflict of interest.

AUTHORS’ CONTRIBUTIONS
JD, CJ, SG, SD, and DL participated in the study concept and design, and collected the data. AA, LM, and DL conducted the quality control of data. AA, SG, CH, and DL participated in the interpretation of data. AA and DL performed cleaning of final dataset, statistical analysis, and prepared the manuscript draft. All authors participated in manuscript editing, review, and approved the final version.

ETHICAL APPROVAL
French Data Protection Authority (CNIL, Commission Nationale de l’Informatique et des Libertés) no. DR-2015-2027; IRB INSERM no. 01-036.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Aviane Auguste https://orcid.org/0000-0003-2536-3716
Danièle Luce https://orcid.org/0000-0002-1708-4584

REFERENCES
1. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today, Lyon, France: International Agency for Research on Cancer, 2018. https://gco.iarc.fr/today Accessed February 26, 2020.
2. Hashibe M, Brennan P, Chuang S-C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. 2009;18:541-550.
3. Di Credico G, Edefonti V, Polese L, et al. Joint effects of intensity and duration of cigarette smoking on the risk of head and neck cancer: a bivariate spline model approach. Oral Oncol. 2019;94:47-57.
4. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709-720.
5. D’Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356:1944-1956.
6. Gillison ML, Alemany L, Snijders PJF, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine. 2012;30:F34-F54.
7. Gillison ML, D’Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16–positive and human papillomavirus type 16–negative head and neck cancers. J Natl Cancer Inst. 2008;100:407-420.
8. Applebaum KM, Furniss CS, Zeka A, et al. Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst. 2007:99:1801-1810.
9. Anantharaman D, Muller DC, Lagiou P, et al. Combined effects of smoking and HPV16 in oropharyngeal cancer. Int J Epidemiol. 2016;45:752-761.
10. Farsi NJ, Rousseau M-C, Schlecht N, et al. Aetiological heterogeneity of head and neck squamous cell carcinomas: the role of human papillomavirus infections, smoking and alcohol. Carcinogenesis. 2017;38:1188-1195.
11. Smith EM, Rubenstein LM, Haugen TH, Hamssikova E, Turek LP. Tobacco and alcohol use increases the risk of both HPV-associated and HPV-independent head and neck cancers. Cancer Causes Control. 2010;21:1369-1378.
12. Auguste A, Dugas J, Menvielle G, Barul C, Richard J-B, Luce D. Social distribution of tobacco smoking, alcohol drinking and obesity in the French West Indies. BMC Public Health. 2019;19:1424.
13. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14:467-475.
14. Termine N, Panzarella V, Falaschini S, et al. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988–2007). Ann Oncol. 2008;19:1681-1690.
15. Mehanna H, Beech T, Nicholson T, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta-analysis of trends by time and region. Head Neck. 2013;35:747-755.
16. Ndiaye C, Mena M, Alemany L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014;15:1319-1331.
17. Ragin C, Liu JC, Jones G, et al. Prevalence of HPV infection in racial–ethnic subgroups of head and neck cancer patients. Carcinogenesis. 2017;38:218-229.
18. Voltzke KJ, Lee Y-CA, Zhang Z-F, et al. Racial differences in the relationship between tobacco, alcohol, and the risk of head and neck cancer: pooled analysis of US studies in the INHANCE Consortium. Cancer Causes Control. 2018;29:619-630.
19. Auguste A, Gaète S, Herrmann-Storck C, et al. Prevalence of oral HPV infection among healthy individuals and head and neck cancer cases in the French West Indies. Cancer Causes Control. 2017;28:1333-1340.
20. Luce D, Stücker I; ICARE Study Group. Investigation of occupational and environmental causes of respiratory cancers (ICARE): a multicenter, population-based case-control study in France. BMC Public Health. 2011;11:928.
21. VanderWeele TJ, Knol MJ. A tutorial on interaction. Epidemiol Methods. 2014;3:33-72.
22. Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations: what is it and how does it work? Int J Methods Psychiatr Res. 2011;20:40-49.
23. Lubin JH, Purdue M, Kelsey K, et al. Total exposure and exposure rate effects for alcohol and smoking and risk of head and neck cancer: a pooled analysis of case-control studies. Am J Epidemiol. 2009;170:937-947.
24. Kawakita D, Matsuo K. Alcohol and head and neck cancer. Cancer Metastasis Rev. 2017;36:425-434.

25. Radoï L, Paget-Bailly S, Cyr D, et al. Tobacco smoking, alcohol drinking and risk of oral cavity cancer by subsite: results of a French population-based case-control study, the ICARE study. Eur J Cancer Prev. 2013;22:268-276.

26. Choi Y-J, Myung S-K, Lee J-H. Light alcohol drinking and risk of cancer: a meta-analysis of cohort studies. Cancer Res Treat. 2018;50:474-487.

27. Menvielle G, Fayossé A, Radoï L, et al. The joint effect of asbestos exposure, tobacco smoking and alcohol drinking on laryngeal cancer risk: evidence from the French population-based case-control study, ICARE. Occup Environ Med. 2016;73:28-33.

28. Pettis S, Masood M, Scully C. The magnitude of tobacco smoking-betel quid chewing-alcohol drinking interaction effect on oral cancer in South-East Asia. A meta-analysis of observational studies. PLoS One. 2013;8:e78999.

29. Chen F, He B-C, Yan L-J, et al. Tea consumption and its interactions with tobacco smoking and alcohol drinking on oral cancer in southeast China. Eur J Clin Nutr. 2017;71:481-485.

30. Cordel N, Ragin C, Trival M, Tressières B, Janky E. High-risk human papillomavirus cervical infections among healthy women in Guadeloupe. Int J Infect Dis. 2015;41:13-16.

31. Smith EM, Ritchie JM, Summersgill KF, et al. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst. 2004;96:449-455.

32. Herrero R, Castellsagué X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003;95:1772-1783.

33. Kreimer AR, Pierce Campbell CM, Lin H-Y, et al. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet. 2013;382:877-887.

34. Beachler DC, Sugar EA, Margolick JB, et al. Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. Am J Epidemiol. 2015;181:40-53.

35. D’Souza G, Fakhry C, Sugar EA, et al. Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer. 2007;121:143-150.

36. Kero K, Rautava J, Syrjänen K, Willberg J, Grenman S, Syrjänen S. Smoking increases oral HPV persistence among men: 7-year follow-up study. Eur J Clin Microbiol Infect Dis. 2014;33:123-133.

37. Edelstein ZR, Schwartz SM, Hawes S, et al. Rates and determinants of oral human papillomavirus infection in young men. Sex Transm Dis. 2012;39:860-867.

38. Pickard RKL, Xiao W, Broussian TR, He X, Gillison ML. The prevalence and incidence of oral human papillomavirus infection among young men and women, aged 18–30 years. Sex Transm Dis. 2012;39:559-566.

39. Louvanto K, Rautava J, Willberg J, et al. Genotype-specific incidence and clearance of human papillomavirus in oral mucosa of women: a six-year follow-up study. PLoS One. 2013;8:e53413.

40. Pierce Campbell CM, Giuliani AR, Torres BN, et al. Salivary secretory leukocyte protease inhibitor (SLPI) and head and neck cancer: the Cancer Prevention Study II Nutrition Cohort. Oral Oncol. 2016;55:1-5.

41. Rautava J, Willberg J, Louvanto K, et al. Prevalence, genotype distribution and persistence of human papillomavirus in oral mucosa of women: a six-year follow-up study. PLoS One. 2012;7:e42171.

42. Quabius ES, Loehr J, Haaser D, et al. Smoking-induced SLPI expression hinders HPV infections also in squamous cell carcinomas of the vulva. Transl Oncol. 2019;12:36-42.

43. Hoffmann M, Quabius ES, Tribius S, et al. Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor. Oncol Rep. 2013;29:1962-1968.

44. Gipson BJ, Robbins HA, Fakhry C, D’Souza G. Sensitivity and specificity of oral HPV detection for HPV-positive head and neck cancer. Oral Oncol. 2018;77:52-56.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Auguste A, Deloumeaux J, Joachim C, et al. Joint effect of tobacco, alcohol, and oral HPV infection on head and neck cancer risk in the French West Indies. Cancer Med. 2020;9:6854–6863. https://doi.org/10.1002/cam4.3327